Celgene Stock Price To Book
Celgene fundamentals help investors to digest information that contributes to Celgene's financial success or failures. It also enables traders to predict the movement of Celgene Stock. The fundamental analysis module provides a way to measure Celgene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celgene stock.
Celgene |
Celgene Company Price To Book Analysis
Celgene's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Celgene Price To Book | 7.45 X |
Most of Celgene's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celgene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
CompetitionBased on the latest financial disclosure, Celgene has a Price To Book of 7.45 times. This is 70.99% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The price to book for all United States stocks is 21.66% higher than that of the company.
Celgene Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Celgene's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Celgene could also be used in its relative valuation, which is a method of valuing Celgene by comparing valuation metrics of similar companies.Celgene is currently under evaluation in price to book category among its peers.
Celgene Fundamentals
| Return On Equity | 1.0E-4 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 51.47 % | |||
| Current Valuation | 85.34 B | |||
| Shares Outstanding | 708.74 M | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 77.62 % | |||
| Number Of Shares Shorted | 12.95 M | |||
| Price To Earning | 13.31 X | |||
| Price To Book | 7.45 X | |||
| Price To Sales | 4.54 X | |||
| Revenue | 16.35 B | |||
| Gross Profit | 14.06 B | |||
| EBITDA | 8.42 B | |||
| Net Income | 5.27 B | |||
| Cash And Equivalents | 9.32 B | |||
| Cash Per Share | 13.15 X | |||
| Total Debt | 20.1 B | |||
| Debt To Equity | 199.90 % | |||
| Current Ratio | 3.44 X | |||
| Book Value Per Share | 9.22 X | |||
| Cash Flow From Operations | 6.35 B | |||
| Short Ratio | 3.45 X | |||
| Earnings Per Share | 7.32 X | |||
| Price To Earnings To Growth | 0.67 X | |||
| Number Of Employees | 8.85 K | |||
| Beta | 1.41 | |||
| Market Capitalization | 77.04 B | |||
| Total Asset | 1.11 B | |||
| Retained Earnings | 21.79 B | |||
| Working Capital | 708.47 M | |||
| Current Asset | 849.88 M | |||
| Current Liabilities | 141.41 M | |||
| Z Score | 69.79 |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Celgene Stock
If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Stocks Directory Find actively traded stocks across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |